NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SLRX

Salarius Pharmaceuticals Inc

Jul 11 • 04:00PM ET

0.7480

Dollar change -0.0310
Percentage change -3.98	%

Healthcare • Biotechnology • USA • NASD

Peers: BLRX ADAP AFMD ANAB IMUX EQ AVIR SYBX CLRB

| Held by: MEDX VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.17	Insider Own	0.68%	Shs Outstand	2.13M	Perf Week	-15.79%
Market Cap	1.59M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.11M	Perf Month	1.57%
Enterprise Value	-0.10M	PEG	-	EPS next Q	-	Inst Own	3.02%	Short Float	33.45%	Perf Quarter	25.08%
Income	-5.57M	P/S	-	EPS this Y	-	Inst Trans	60.63%	Short Ratio	0.58	Perf Half Y	-56.26%
Sales	0.00M	P/B	25.17	EPS next Y	-	ROA	-154.23%	Short Interest	0.71M	Perf YTD	-59.35%
Book/sh	0.03	P/C	0.88	EPS next 5Y	-	ROE	-300.16%	52W High	7.20 -89.61%	Perf Year	-72.60%
Cash/sh	0.85	P/FCF	-	EPS past 3/5Y	54.55% 57.63%	ROIC	-9003.36%	52W Low	0.45 65.52%	Perf 3Y	-98.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	21.42% 16.71%	Perf 5Y	-99.75%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	76.18%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	41.76	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.89	EPS Q/Q	68.59%	SMA20	-16.98%	Beta	0.47	Target Price	26.00
Payout	-	Debt/Eq	1.83	Sales Q/Q	-	SMA50	-9.00%	Rel Volume	0.16	Prev Close	0.78
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	-42.12%	Avg Volume	1.21M	Price	0.75
IPO	Jan 29, 2015	Option/Short	No / Yes	EPS/Sales Surpr.	0.00% -	Trades		Volume	187,440	Change	-3.98%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-27-20	Initiated	Ladenburg Thalmann	Buy	$3.80

Jul-09-25 08:30AM	Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies (GlobeNewswire)
May-14-25 05:33PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance) +11.53%
Apr-16-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board (GlobeNewswire) -6.71%
Mar-26-25 08:00AM	Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses (GlobeNewswire) -9.78%
Mar-24-25 08:00AM	Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Feb-03-25 08:00AM	Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers (GlobeNewswire)
Jan-13-25 08:00AM	Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement (GlobeNewswire) +134.50%
Nov-14-24 07:25PM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Aug-09-24 05:21PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) +11.65% -5.22%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -20.51%
Jun-17-24 08:00AM	Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting (GlobeNewswire)
Jun-12-24 08:00AM	Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split (GlobeNewswire)
May-13-24 10:53PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace) -7.12%
04:43PM	Salarius: Q1 Earnings Snapshot (Associated Press Finance)
Mar-22-24 09:52PM	SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace) +5.96% -17.74%
04:34PM	Loading…
04:34PM	Salarius: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-22-24 08:00AM	Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses (GlobeNewswire)
Jan-16-24 08:00AM	Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Jan-03-24 08:30AM	Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment (GlobeNewswire)
Nov-10-23 05:03AM	Salarius: Q3 Earnings Snapshot (Associated Press Finance)
Nov-07-23 08:30AM	Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program (GlobeNewswire)
Aug-10-23 05:10PM	Salarius: Q2 Earnings Snapshot (Associated Press Finance) -9.32% -5.92%
04:05PM	Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-09-23 07:39AM	SLRX Pursuing Strategic Alternatives (Zacks) -9.96%
Aug-08-23 04:05PM	Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources (GlobeNewswire)
Jul-11-23 09:00AM	SLRX Continues Cancer Fight with Phase I Trial Approval (Zacks) -12.41%
08:30AM	Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients (GlobeNewswire)
Jun-12-23 08:00AM	Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress (GlobeNewswire)
May-16-23 04:05PM	Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
08:00AM	Loading…
May-12-23 08:00AM	Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
May-11-23 08:20AM	Salarius: Q1 Earnings Snapshot (AP Finance) -5.41%
08:00AM	Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-09-23 08:00AM	FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma (GlobeNewswire) -16.20%
07:34AM	SLRX: Fighting Cancer Through Two Paths (Zacks Small Cap Research)
May-01-23 08:30AM	Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 (GlobeNewswire)
Apr-20-23 08:30AM	Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting (GlobeNewswire) -10.75%
Apr-04-23 04:02PM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference (GlobeNewswire) -12.32% -5.48%
12:00PM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 5, 2023 (GlobeNewswire)
Mar-27-23 08:30AM	Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-23 11:00AM	Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia (GlobeNewswire)
Feb-16-23 08:30AM	Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas (GlobeNewswire)
Jan-27-23 08:30AM	Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) -5.47%
Jan-19-23 08:30AM	Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit (GlobeNewswire) +52.99%
Jan-05-23 08:00AM	Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders (GlobeNewswire)
Dec-13-22 08:01AM	Investigators Present Clinical Data on Salarius Pharmaceuticals Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire) -5.32%
08:00AM	Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-22 08:00AM	Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH (GlobeNewswire)
Dec-01-22 08:00AM	Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -5.18%
Nov-10-22 08:30AM	Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-22 09:57AM	Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting (GlobeNewswire)
Oct-27-22 08:30AM	Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -14.40%
Oct-19-22 08:30AM	Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference (GlobeNewswire) -15.73%
Oct-18-22 08:30AM	Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -45.18%
Oct-14-22 08:43AM	Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split (GlobeNewswire) -13.81%
Sep-20-22 12:00PM	Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference (GlobeNewswire)
Sep-13-22 08:00AM	Salarius Pharmaceuticals CEO Issues Letter to Stockholders (GlobeNewswire) +10.10%
Aug-22-22 08:30AM	Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewings Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire) -9.29%
Aug-08-22 08:30AM	Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +9.95%
Aug-04-22 08:30AM	Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas (GlobeNewswire)
Aug-02-22 08:30AM	Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement (GlobeNewswire) -6.07%
Jul-29-22 09:15AM	Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022 (GlobeNewswire)
Jun-09-22 07:33AM	Salarius Pharmaceuticals to Participate in BIO International Convention 2022 (GlobeNewswire)
May-18-22 04:10PM	Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) +20.62% -9.12%
May-12-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results (GlobeNewswire) +38.75% -15.36%
May-11-22 04:05PM	Salarius Pharmaceuticals Completes SP-3164 Pre-Investigational New Drug Meeting Process with the U.S. Food and Drug Administration (GlobeNewswire) -16.93%
May-05-22 07:30AM	Salarius Pharmaceuticals to Report First Quarter 2022 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Apr-22-22 08:30AM	Salarius Pharmaceuticals, Inc. Announces $2.3 Million Registered Direct Offering (GlobeNewswire) -20.54%
Mar-10-22 04:05PM	Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2021 Financial Results (GlobeNewswire) +33.40% -26.62%
Mar-03-22 07:31AM	Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Feb-17-22 08:01AM	Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational 2022 Virtual Conference (GlobeNewswire)
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 (GlobeNewswire)
Feb-08-22 08:00AM	Salarius Pharmaceuticals to Participate in the 2022 BIO CEO & Investor Conference (GlobeNewswire)
Feb-03-22 07:30AM	Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program (GlobeNewswire)
Jan-14-22 01:52PM	Salarius expands oncology drug pipeline with DeuteRx portfolio acquisition (American City Business Journals)
Jan-13-22 07:00AM	Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC (GlobeNewswire)
Jan-06-22 12:45PM	Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022" (GlobeNewswire) -6.06%
Dec-29-21 08:03AM	Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial (GlobeNewswire) -6.19%
Dec-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (PR Newswire)
Dec-15-21 08:31AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum (GlobeNewswire)
Dec-14-21 08:35AM	Virtual Conference for Life Sciences Companies Broadcast Live December 16th (PR Newswire)
Nov-29-21 08:01AM	Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference (GlobeNewswire)
Nov-04-21 04:05PM	Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -9.30%
Oct-28-21 03:06PM	Will Salarius (SLRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-26-21 08:01AM	Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress (GlobeNewswire)
Oct-07-21 09:05AM	Salarius Pharmaceuticals and Nationwide Childrens Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-05-21 08:01AM	Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference (GlobeNewswire)
Sep-30-21 04:35PM	Salarius Pharmaceuticals and Nationwide Childrens Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-21 07:01AM	Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas (GlobeNewswire)
Sep-27-21 08:03AM	Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference (GlobeNewswire) -5.22%
Sep-22-21 07:33AM	Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership (GlobeNewswire)
Sep-20-21 08:35AM	Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing (GlobeNewswire)
07:33AM	Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index (GlobeNewswire)
Sep-15-21 08:03AM	Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum (GlobeNewswire)
Sep-10-21 08:35AM	Life Sciences Virtual Investor Conference: Company Executives Present Live September 16th (GlobeNewswire)
Sep-08-21 08:13AM	Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-12-21 02:00PM	Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational (GlobeNewswire)
09:00AM	Diamond Equity Research Emerging Growth Invitational Summer 2021 Spotlight Virtual Conference (GlobeNewswire)
Aug-10-21 06:16AM	Here's Why We're Not Too Worried About Salarius Pharmaceuticals' (NASDAQ:SLRX) Cash Burn Situation (Simply Wall St.)

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLRX

Salarius Pharmaceuticals Inc

Upgrade your FINVIZ experience